Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Purpose: Omidenepag isopropyl (OMDI) is a prodrug of OMD, a selective, nonprostaglandin, prostanoid EP2 receptor agonist. This phase I study aimed to investigate the pharmacokinetic properties, safety, and intraocular pressure (IOP)-lowering efficacy of OMDI. Methods: Fourteen healthy male volunteer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Ocul Pharmacol Ther
Hauptverfasser: Aihara, Makoto, Lu, Fenghe, Kawata, Hisashi, Tanaka, Yuki, Yamamura, Kenzo, Odani-Kawabata, Noriko, Shams, Naveed K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Mary Ann Liebert, Inc., publishers 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6918846/
https://ncbi.nlm.nih.gov/pubmed/31674861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jop.2019.0044
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge